164 related articles for article (PubMed ID: 33720014)
1. Association Between Prolactinoma and Body Mass Index.
Al Sabie F; Tariq Z; Erickson D; Donegan D
Endocr Pract; 2021 Apr; 27(4):312-317. PubMed ID: 33720014
[TBL] [Abstract][Full Text] [Related]
2. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
[TBL] [Abstract][Full Text] [Related]
3. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Greenman Y; Tordjman K; Stern N
Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
5. The epidemiology of prolactinomas.
Ciccarelli A; Daly AF; Beckers A
Pituitary; 2005; 8(1):3-6. PubMed ID: 16411062
[TBL] [Abstract][Full Text] [Related]
6. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
Chanson P; Maiter D
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
[TBL] [Abstract][Full Text] [Related]
7. BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort.
Jiang XB; He DS; Mao ZG; Fan X; Lei N; Hu B; Song BB; Zhu YH; Wang HJ
Tumour Biol; 2013 Apr; 34(2):1171-6. PubMed ID: 23345015
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.
Larouche V; Correa JA; Cassidy P; Beauregard C; Garfield N; Rivera J
Pituitary; 2016 Apr; 19(2):202-9. PubMed ID: 26700946
[TBL] [Abstract][Full Text] [Related]
9. The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.
Faje A; Jones P; Swearingen B; Tritos NA
Endocr Pract; 2022 Jun; 28(6):572-577. PubMed ID: 35339688
[TBL] [Abstract][Full Text] [Related]
10. NUTRITIONAL AND METABOLIC ASSESSMENT IN OVERWEIGHT PATIENTS WITH AND WITHOUT HYPERPROLACTINEMIA CAUSED BY PROLACTINOMA.
Breyer Freitas B; Rothen RE; Zeni D; Garcia Soares Leães C; Costa Oliveira M; Michielin Busnello F; Fernanda Semmelmann Pereira-Lima J
Nutr Hosp; 2015 Nov; 32(5):2030-7. PubMed ID: 26545657
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Disorders During Prolactinomas.
Elleuch M; Ben Bnina M; Loukil F; Hadj Kacem F; Boujelben K; Mnif M; Mnif F; Charfi N; Rekik N; Ben Salah D; Abid M
Metab Syndr Relat Disord; 2024 Mar; 22(2):85-89. PubMed ID: 38232370
[TBL] [Abstract][Full Text] [Related]
12. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
[TBL] [Abstract][Full Text] [Related]
13. Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas.
Radaelli E; Arnold A; Papanikolaou A; Garcia-Fernandez RA; Mattiello S; Scanziani E; Cardiff RD
Vet Pathol; 2009 Jul; 46(4):736-45. PubMed ID: 19276050
[TBL] [Abstract][Full Text] [Related]
14. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
15. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
16. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
17. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
18. Development of acromegaly in patients with prolactinomas.
Andersen M; Hagen C; Frystyk J; Schroeder HD; Hagen C
Eur J Endocrinol; 2003 Jul; 149(1):17-22. PubMed ID: 12824861
[TBL] [Abstract][Full Text] [Related]
19. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass.
Cheng JS; Salinas R; Molinaro A; Chang EF; Kunwar S; Blevins L; Aghi MK
J Clin Neurosci; 2015 Jan; 22(1):155-60. PubMed ID: 25481269
[TBL] [Abstract][Full Text] [Related]
20. Growth potential of female prolactinomas.
Nishioka H; Ito H; Haraoka J; Hirano A
Surg Neurol; 2001 Apr; 55(4):213-7. PubMed ID: 11358591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
